Skip to content
Research

27 Oct 2026 · 4 min read

Decoding Dengue in Sri Lanka: From Genomic Discovery to National Impact

Collaborative research initiative

Dr. Tharmini SundralingamSenior Scientist

Genelabs X contributed to dengue genomic research in Sri Lanka through a collaborative initiative with General Sir John Kotelawala Defence University (KDU) and Takeda Pharmaceutical Company, USA. The project focused on sequencing dengue virus genomes representing all four serotypes circulating in Sri Lanka, supporting research into viral diversity, molecular epidemiology and vaccine development.

Decoding Dengue in Sri Lanka: From Genomic Discovery to National Impact

Our Efforts: From Laboratory Workflow to Genomic Data

A key achievement of the project was the development and optimization of a comprehensive laboratory and bioinformatics workflow for dengue viral genome sequencing. The process integrated molecular biology techniques, next-generation sequencing (NGS) and bioinformatics to generate and assess viral genome consensus sequences.

From Laboratory Workflow to Genomic Data

Through this initiative, the team generated sequences from 50 dengue virus samples representing all four stereotypes.

Sample pie chart

Research Publication, Scientific Communication and NCBI Submission

The project contributed to the scientific understanding of dengue viruses circulating in Sri Lanka, with findings supporting the research publication “Identifying the strains of dengue circulating in the Western Province of Sri Lanka during 2019–2022.”

URL:https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0003150

The work was also communicated through a scientific conference presentation.

To support further research and data accessibility, selected dengue viral sequences were submitted to the National Center for Biotechnology Information (NCBI) GenBank database. These submissions made valuable genomic information available to the wider scientific community.

Selected GenBank accessions include:

  • OL587817.1 – Dengue virus 1, isolate F-095
  • OK598125.1 – Dengue virus 3, isolate F-001
  • OK598124.1 – Dengue virus 3, isolate F-030
  • OK631736.1 – Dengue virus 3, isolate F-047
  • OK598123.1 – Dengue virus 3, isolate F-124

These contributions helped establish a local genomic resource for investigating dengue virus diversity, genetic variation and molecular epidemiology.

Contributing to Research Relevant to Dengue Vaccine Development

Understanding the genetic diversity of dengue viruses is important for research aimed at improving disease prevention and control. Genomic data from locally circulating strains can help researchers compare viral genomes, investigate genetic variation and build a better understanding of dengue virus populations.

While vaccine development requires extensive research, evaluation and validation, genomic sequencing provides an important part of the evidence base that can inform this work. Through its collaboration with KDU and Takeda, Genelabs X contributed locally generated genomic data relevant to the wider research landscape supporting dengue vaccine development.

Proud to Contribute to Our Nation

At Genelabs X, we are proud to have contributed, to scientific research addressing a significant public health challenge in Sri Lanka. Our efforts supported dengue genomic research and broader research initiatives relevant to vaccine development.

Our contributions included:

  • Developing an optimized workflow for dengue viral genome sequencing.
  • Generating genomic sequences from 50 dengue virus samples representing all four stereotypes.
  • Sharing selected genomic data with the global scientific community through NCBI GenBank submissions.
  • Supporting research into dengue virus diversity and molecular epidemiology in Sri Lanka.
  • Contributing locally generated genomic data to the broader research efforts supporting dengue vaccine development.

We believe that even small scientific contributions can make a meaningful difference when combined with collaborative research and a shared commitment to advancing public health.

Our Dengue Research and Diagnostic Services: Detection, Serotyping and Genomic Sequencing

Our Dengue Research and Diagnostic Services: Detection, Serotyping and Genomic Sequencing

Building on our experience in dengue genomic research, Genelabs X offers molecular testing and sequencing capabilities to support research projects and dengue surveillance.

  1. 01Dengue Infection Detection: Molecular testing to detect dengue virus infection.
  2. 02Dengue Serotyping: Identification of dengue virus serotypes to support clinical investigations and research.
  3. 03Dengue viral genome sequencing: To support research projects investigating viral diversity, molecular epidemiology, genetic variation and other research questions.

We welcome collaborations with researchers and institutions seeking dengue molecular testing, serotyping or genome sequencing services for research purposes.

Written by

Dr. Tharmini Sundralingam

Senior Scientist

View All Insights
  • Paediatric Care

    Research

    From Diagnostic Uncertainty to Answers: How Genomic Sequencing Is Transforming Paediatric Care

    How advanced DNA analysis is helping identify rare genetic conditions in children, inform clinical decisions, and support families in Sri Lanka.

    Read More
  • WORKSHOP ON BIOINFORMATICS FOR GENOMIC MEDICINE 2025

    Training

    From Training to Patient Care: Advancing Genomic Medicine in Sri Lanka

    Genelabs Medical (Pvt) Ltd, together with the U.S. Embassy in Sri Lanka, organised the Bioinformatics for Genomic Medicine 2025 training programme.

    Read More
  • A new CFTR gene panel aims to bring more comprehensive genetic testing closer to local patients and families.

    Clinical

    A Step Forward for Cystic Fibrosis Genetic Testing in Sri Lanka

    A new CFTR gene panel aims to bring more comprehensive genetic testing closer to local patients and families.

    Read More

Stay informed

New research and programmes in your inbox.

A short monthly update. No spam, unsubscribe anytime.